---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-123265"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:36:16.425440+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Legacy OnKure posts $35.2M net loss in 9mo; auditor switched to KPMG post-merger

## Summary
- Net loss of $35.2M for nine months ended Sep 30, 2024, vs $25.9M in prior year.
- Cash and equivalents $8.0M as of Sep 30, 2024; accumulated deficit $137.3M.
- Ernst & Young dismissed as auditor; KPMG engaged as new independent registered public accounting firm.
- Merger with Reneo closed Oct 4, 2024; management expects combined cash to fund operations for at least 12 months.
- Convertible notes payable of $6.0M issued in 2024, net of $142k issuance costs.

## SEC filing metadata
- accession: 0000950170-24-123265
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 4.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000095017024123265/0000950170-24-123265-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000095017024123265/okur-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-123265
- JSON: https://secwatch.observer/filing/0000950170-24-123265.json
- Plain text: https://secwatch.observer/filing/0000950170-24-123265.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.